Bellevue Life Sciences Acquisition Corp.
BLAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $0 |
| % Growth | -44.7% | 49.2% | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 41.7% | 2.9% | 22.2% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $2 |
| SG&A Expenses | $4 | $5 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $5 | $3 | $2 |
| Operating Income | -$4 | -$5 | -$3 | -$2 |
| % Margin | -605.9% | -460.5% | -383.3% | – |
| Other Income/Exp. Net | -$1 | $0 | -$8 | $0 |
| Pre-Tax Income | -$4 | -$5 | -$11 | -$2 |
| Tax Expense | -$1 | $0 | $0 | -$1 |
| Net Income | -$3 | -$5 | -$11 | -$2 |
| % Margin | -508.9% | -460.2% | -1,496.6% | – |
| EPS | -0.71 | -1.17 | -2.54 | -0.45 |
| % Growth | 39.3% | 53.9% | -464.4% | – |
| EPS Diluted | -0.71 | -1.17 | -2.54 | -0.45 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$1 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | $0 | -$5 | -$3 | -$2 |
| % Margin | 0% | -460.5% | -383.3% | – |